← All trials
NCT06969170
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 6, 2025
- Primary completion
- Jun 1, 2026
- Completion date
- Aug 30, 2026
- First posted
- May 13, 2025
- Last posted
- May 13, 2025
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Queen's University, BelfastLead sponsor
- Diamond Therapeutics Inc.Collaborator
- Queen's University, BelfastSponsor investigator
- Kingston Health Sciences CentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.